Design: Randomized, double-blind, placebo-controlled study with 4 weeks of treatment with
either fiber supplements or placebo.
Primary outcome: variation in SCFA between baseline and week 4. Secondary outcomes :
variations in gut microbiota, disease activity (DAS28, RAID), immune cells (regulatory T and
B cells, Th17) and heart-rate variability.
Population: 29 patients with rheumatoid arthritis treated with only csDMARDs and a moderate
disease activity will be recruited in each arm and 29 controls with mechanic disease
(osteoarthritis, tendinitis).
Collection: Blood, feces, disease activity and heart rate variability will be collected at
baseline and week 4.
Phase:
N/A
Details
Lead Sponsor:
University Hospital, Montpellier
Collaborators:
Institut de Génétique Moléculaire de Montpellier University of Sydney